OPKO Health

Company Profile

A New Direction in SHPT

Indication and Limitations of Use

Rayaldee® (calcifediol) extended-release 30 mcg capsules is indicated for the treatment of secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease and serum total 25-hydroxyvitamin D levels less than 30 ng/mL. Rayaldee is not indicated in patients with stage 5 chronic kidney disease or end-stage renal disease on dialysis.

Please see Full Prescribing information at Rayaldee.com.


4400 Biscayne Blvd.
Miami, FL 33137